Literature DB >> 23838347

Plzf drives MLL-fusion-mediated leukemogenesis specifically in long-term hematopoietic stem cells.

Ryoichi Ono1, Masahiro Masuya, Hideaki Nakajima, Yutaka Enomoto, Eri Miyata, Akihide Nakamura, Satomi Ishii, Kei Suzuki, Fumi Shibata-Minoshima, Naoyuki Katayama, Toshio Kitamura, Tetsuya Nosaka.   

Abstract

Oncogenic transformation requires unlimited self-renewal. Currently, it remains unclear whether a normal capacity for self-renewal is required for acquiring an aberrant self-renewal capacity. Our results in a new conditional transgenic mouse showed that a mixed lineage leukemia (MLL) fusion oncogene, MLL-ENL, at an endogenous-like expression level led to leukemic transformation selectively in a restricted subpopulation of hematopoietic stem cells (HSCs) through upregulation of promyelocytic leukemia zinc finger (Plzf). Interestingly, forced expression of Plzf itself immortalized HSCs and myeloid progenitors in vitro without upregulation of Hoxa9/Meis1, which are well-known targets of MLL fusion proteins, whereas its mutant lacking the BTB/POZ domain did not. In contrast, depletion of Plzf suppressed the MLL-fusion-induced leukemic transformation of HSCs in vitro and in vivo. Gene expression analyses of human clinical samples showed that a subtype of PLZF-high MLL-rearranged myeloid leukemia cells was closely associated with the gene expression signature of HSCs. These findings suggested that MLL fusion protein enhances the self-renewal potential of normal HSCs to develop leukemia, in part through a Plzf-driven self-renewal program.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23838347     DOI: 10.1182/blood-2012-09-456665

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  PLZF regulates CCR6 and is critical for the acquisition and maintenance of the Th17 phenotype in human cells.

Authors:  Satya P Singh; Hongwei H Zhang; Hsinyi Tsang; Paul J Gardina; Timothy G Myers; Vijayaraj Nagarajan; Chang Hoon Lee; Joshua M Farber
Journal:  J Immunol       Date:  2015-04-01       Impact factor: 5.422

2.  Eya2, a Target Activated by Plzf, Is Critical for PLZF-RARA-Induced Leukemogenesis.

Authors:  Ryoichi Ono; Masahiro Masuya; Satomi Ishii; Naoyuki Katayama; Tetsuya Nosaka
Journal:  Mol Cell Biol       Date:  2017-06-15       Impact factor: 4.272

3.  ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.

Authors:  Giuseppe Germano; Giulia Morello; Sanja Aveic; Marica Pinazza; Sonia Minuzzo; Chiara Frasson; Luca Persano; Paolo Bonvini; Giampietro Viola; Silvia Bresolin; Claudia Tregnago; Maddalena Paganin; Martina Pigazzi; Stefano Indraccolo; Giuseppe Basso
Journal:  Oncotarget       Date:  2017-04-18

4.  Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves' disease.

Authors:  Xinxin Chen; Fengjiao Huang; Yicheng Qi; Mengxi Zhou; Qinglei Yin; Ying Peng; Yulin Zhou; Guang Ning; Shu Wang
Journal:  J Transl Med       Date:  2018-07-05       Impact factor: 5.531

Review 5.  Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.

Authors:  Kevin Dzobo; Dimakatso Alice Senthebane; Chelene Ganz; Nicholas Ekow Thomford; Ambroise Wonkam; Collet Dandara
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

6.  Molecular characterization of an MLL1 fusion and its role in chromosomal instability.

Authors:  Sreejit Parameswaran; Frederick S Vizeacoumar; Kalpana Kalyanasundaram Bhanumathy; Fujun Qin; Md Fahmid Islam; Behzad M Toosi; Chelsea E Cunningham; Darrell D Mousseau; Maruti C Uppalapati; Peter C Stirling; Yuliang Wu; Keith Bonham; Andrew Freywald; Hui Li; Franco J Vizeacoumar
Journal:  Mol Oncol       Date:  2018-12-31       Impact factor: 6.603

7.  A Novel Inducible Mouse Model of MLL-ENL-driven Mixed-lineage Acute Leukemia.

Authors:  Vaia Stavropoulou; Marwa Almosailleakh; Hélène Royo; Jean-François Spetz; Sabine Juge; Laurent Brault; Patrick Kopp; Michelina Iacovino; Michael Kyba; Alexandar Tzankov; Michael B Stadler; Gianni Cazzaniga; Antoine H F M Peters; Juerg Schwaller
Journal:  Hemasphere       Date:  2018-06-12

Review 8.  Genetically engineered mouse models of human B-cell precursor leukemias.

Authors:  Julia Hauer; Arndt Borkhardt; Isidro Sánchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 9.  Role of PLZF as a tumor suppressor in prostate cancer.

Authors:  Yang Jin; Hatice Zeynep Nenseth; Fahri Saatcioglu
Journal:  Oncotarget       Date:  2017-08-02

Review 10.  Advances of Zinc Signaling Studies in Prostate Cancer.

Authors:  Dangdang Li; Daniel B Stovall; Wenmeng Wang; Guangchao Sui
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.